

Ref. No: 2442
Date: 19/03/26
Subject: Oncology – Myelofibrosis

REQUEST

Does your trust treat Polycythaemia Vera (ICD10 code D45)? If no, please provide the name of the trust that you refer Polycythaemia Vera patients to?

Q2. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

- Myelofibrosis (ICD10 code D47.4)
- Polycythaemia Vera (ICD10 code D45)
- Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005)

Q3. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

- Momelotinib
- Fedratinib

Q4. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?

- Hydroxycarbamide
- Interferon therapy

Q5. Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy

(First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.)

Treatment	First systemic therapy	Received prior systemic therapy
Ruxolitinib (Jakavi)		
Fedratinib (Inrebic)		
Momelotinib (Omjjara)		

RESPONSE

Does your trust treat Polycythaemia Vera (ICD10 code D45)? If no, please provide the name of the trust that you refer Polycythaemia Vera patients to?

Q2. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

- Myelofibrosis (ICD10 code D47.4) - 0
- Polycythaemia Vera (ICD10 code D45) - <5
- Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005) - 0

Q3. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

- Momelotinib - <5
- Fedratinib - 0

Q4. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?

- Hydroxycarbamide - <5
- Interferon therapy - 0

Q5. Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy

(First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy,

JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.)

Treatment	First systemic therapy	Received prior systemic therapy
Ruxolitinib (Jakavi)	0	0
Fedratinib (Inrebic)	0	0
Momelotinib (Omjjara)	<5	0